Eisai's farletuzumab misses in ovarian cancer

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said IV farletuzumab plus carboplatin and taxane chemotherapy missed the primary

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE